The pharmaceutical industry seems besieged on all sides, with declining R&D productivity, expiring patents on blockbuster products and relentless downward pricing pressure forcing companies to look closely at the bottom line. One affect of this onslaught has been an upsurge in the level of M&A activity as players within the industry consolidate to cut costs, expand research pipelines and lengthen geographic reach.
25-Aug-2014 - Roche has bought InterMune for $8.3bn (€6.3bn) and says it will continue contracts with Catalent and two API suppliers for the manufacture of its lead product Esbriet (pirfenidone).
06-Aug-2014 - Actavis says it is excited to partner with AstraZeneca over its long-acting muscarinic antagonist/beta-agonist (LAMA/LABA) fixed dose combination respiratory drug following the latter’s acquisition of Almirall.
04-Aug-2014 - AstraZeneca has bolstered its respiratory portfolio and added new bronchodilator technologies through the $875m (€650m) acquisition of Almirall.
29-Jul-2014 - Reckitt Benckiser’ opioid addiction drug Suboxone delivered by sublingual film has shown a 'surprising' level of resilience against generic competition, the firm says as it plans to spin-out its pharmaceutical business....
28-Jul-2014 - Hikma has bought defunct manufacturer Ben Venue and says it could reactivate the site in the long-term, despite the transfer of equipment across its sterile injectables network.
22-Jul-2014 - Drugmakers are bringing sterile injectables capacity back in-house according to a Frost & Sullivan analyst, who says industry risk aversion is the key driver.
22-Jul-2014 - Botox maker Allergan announced sales and earnings per share growth above the high end of its expectations, but it will cut 1,500 jobs, or about 13% of its workforce as...
10-Jul-2014 - Actavis says it is closing facilities in St. Louis, Missouri affecting 190 jobs a week after completing the $28bn (€21bn) acquisition of Forest Laboratories.
08-Jul-2014 - M+W says a lack of synergies with its engineering and construction business drove the decision to sell its automation divison to ATS for €255m ($348m).
12-Jun-2014 - Teva could halve its manufacturing network as part of its $2bn-a-year efficiency programme says CFO Eyal Desheh, with most cuts hitting its core generics business.
10-Jun-2014 - Merck & Co. says the $3.85bn (€2.8bn) acquisition of Idenix will springboard its oral hepatitis C programme but according to an analyst is unlikely to threaten Gilead’s $1,000 pill Sovaldi.
27-May-2014 - Pfizer has confirmed it has dropped a £69bn ($118bn) bid to buy fellow pharma giant AstraZeneca following yesterday’s acquisition deadline.
06-May-2014 - Bayer says it will become the OTC leader in North America having acquired Merck & Co.’s consumer health business for $14.2bn (€10.2bn), in the latest shift in Big Pharma assets....
05-May-2014 - Pfizer will keep a “substantial” level of manufacturing in the UK if it takes over AstraZeneca, said the CEO in a letter to the country’s Prime Minister.
28-Apr-2014 - Endo Pharmaceuticals, which previously lost a bid to acquire a migraine treatment, has now acquired worldwide rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use, which is a needle-free delivery system for...
28-Apr-2014 - AstraZeneca says Pfizer has “very significantly undervalued” the company after confirming rumours it had received an offer worth £59bn ($100bn).
24-Apr-2014 - Opko Health has agreed to acquire Inspiro Medical, an Israeli medical device company developing a new platform to deliver small molecule drugs such as corticosteroids and beta agonists or larger molecules...
22-Apr-2014 - With Pfizer rumoured to be on the brink of a mega-merger with AstraZeneca, in-Pharmatechnologist.com brings you an interactive view of what £60bn ($101bn) could get.
17-Apr-2014 - Albemarle has agreed to sell its ibuprofen business to US chemical intermediates firm SI Group in a deal that will also see it divest the anaesthetic agent, propofol.
07-Apr-2014 - Regulatory compliance will be the number one focus for Sun Pharma, the company says, following its $3.2bn (€2.3bn) takeover of Indian generics firm Ranbaxy.
01-Apr-2014 - Lupin has bought Mexican eye drugmaker Grin in a deal that gives it a “bridgehead” to grow its API and generics business in the region.
18-Mar-2014 - The Board of Directors at Indian firm Orchid has approved the sale of its API business to Hospira, bringing the acquisition a step closer to completion.
17-Mar-2014 - Twin changes at AstraZeneca's MedImmune kick off this week's gallery, as well as jobs news from Europe
18-Feb-2014 - Actavis has confirmed it will acquire Forest Laboratories in a deal worth up to $25bn (€18bn) following rumours last night.
06-Feb-2014 - An increased trend in dealmaking for targeted drug delivery last year will continue to drive partnerships in 2014, according to a pharmaceutical partnering expert.